Previous 10 | Next 10 |
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make co...
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAAC...
SAExploration Holdings (NASDAQ: SAEX ) +177% on $27M new project in Greece. More news on: SAExploration Holdings, Inc., B.O.S. Better Online Solutions Ltd., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
Celldex (NASDAQ: CLDX ): Q4 GAAP EPS of -$0.64 beats by $0.29 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. “We are pleased that Celldex entered 2020 with significant momentum, following excit...
Gainers: Trans World Entertainment (NASDAQ: TWMC ) +97% . More news on: Trans World Entertainment Corporation, Avadel Pharmaceuticals plc, Celldex Therapeutics, Inc., Stocks on the move, , Read more ...
DPW Holdings (NYSEMKT: DPW ) +38% after defense unit gets $1.4M follow-on order . More news on: DPW Holdings, Inc., California Resources Corporation, Baudax Bio, Inc., Stocks on the move, , Read more ...
Celldex Therapeutics (NASDAQ: CLDX ) initiated with Overweight rating and $8 (252% upside) price target at Cantor Fitzgerald. Shares up 10% premarket. More news on: Celldex Therapeutics, Inc., Editas Medicine, Inc., Guardant Health, Inc., Healthcare stocks news, Stocks on the m...
HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its act...
Celldex (NASDAQ: CLDX ): Q3 GAAP EPS of -$0.75 beats by $0.09 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...